Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 22;10(8):1594.
doi: 10.3390/healthcare10081594.

Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?

Denis Horgan  1   2 , Tanja Spanic  3 , Kathi Apostolidis  4 , Giuseppe Curigliano  5   6 , Joanna Chorostowska-Wynimko  7 , Hans-Peter Dauben  8 , Jonathan A Lal  2   9 , Rafal Dziadziuszko  10 , Christine Mayer-Nicolai  11 , Marta Kozaric  1 , Bengt Jönsson  12 , Iñaki Gutierrez-Ibarluzea  13 , Marie-Helene Fandel  14 , Ruth Lopert  15
Affiliations

Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?

Denis Horgan et al. Healthcare (Basel). .

Abstract

Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that investment in research and development (R&D) for innovative medicines and treatments is essential for making progress in preventing and treating diseases. Ahead of the legislative process, which should begin by the end of 2022, discussions focus on how Europe can best promote the huge potential benefits of new science and technology within the regulatory framework. The challenges in European healthcare were spelled out by the panellists at the roundtable organised by European Alliance for Personalised Medicine (EAPM). Outcomes from panellists' discussions have been summarized and re-arranged in this paper under five headings: innovation, unmet medical need, access, security of supply, adapting to progress, and efficiency. Some of the conclusions that emerged from the panel are a call for a better overall holistic vision of the future of pharmaceuticals and health in Europe and a collaborative effort among all stakeholders, seeing the delivery of medicines as part of a broader picture of healthcare.

Keywords: access; efficiency; innovation; personalized medicine; pharmaceutical legislation; policy framework; regulation; security of supply; unmet medical need.

PubMed Disclaimer

Conflict of interest statement

Chorostowska-Wynimko reports grants, personal fees, and non-financial support from Grifols, grants, personal fees and non-financial support from AstraZ˛en˛eca, grants, personal fees and non-financial support from Pfizer, personal fees and non-financial support from IVSD, personal fees from BMS, personal fees from Novartis, personal fees from Chiesi, personal fees from Roche, grants and personal fees from Boehringer-lngelheim, grants, personal fees and non-financial support from CSL Behring, grants, personal fees and non-financial support from CelonPharma, personal fees from Amgen, personal fees from Adamed, grants and personal fees from Mereo Biopharma, personal fees from Takeda, outside the submitted work; Rafal Dziadziuszko received honoraria for lectures/ advisory boards: Astra Zeneca, Roche, Takeda, Pfizer, Novartis, MSD, Karyopharm, Bristol-Myers Squibb; D.H. and M.K. are employees of the European Alliance for Personalised Medicine, which receives funding from both the public and private sectors. Marie-Helene Fandal is an employee of SANOFI.

Figures

Figure 1
Figure 1
Applied research strategy; after literature search of relevant articles, an expert panel was organised to discuss the proposed topic and literature findings.
See this image and copyright information in PMC

References

    1. Horgan D., Jansen M., Leyens L., Lal J.A., Sudbrak R., Hackenitz E., Bußhoff U., Ballensiefen W., Brand A. An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe. Public Health Genom. 2014;17:287–298. doi: 10.1159/000368034. - DOI - PubMed
    1. Horgan D., Borisch B., Richer E., Bernini C., Kalra D., Lawler M., Ciliberto G., Van Poppel H., Paradiso A., Riegman P., et al. Propelling Health Care into the Twenties. Biomed. Hub. 2020;5:508300. doi: 10.1159/000508300. - DOI - PMC - PubMed
    1. Thimbleby H. Technology and the Future of Healthcare. J. Public Health Res. 2013;2:e28. doi: 10.4081/jphr.2013.e28. - DOI - PMC - PubMed
    1. Busse R., Klazinga N., Panteli D., Quentin W. Improving Healthcare Quality in Europe: Characteristics, Effectiveness and Implementation of Different Strategies. World Health Organization; Geneva, Switzerland: 2019. - PubMed
    1. European Commission . Pharmaceutical Strategy for Europe. European Commission; Brussels, Belgium: 2020.